Header Logo

Connection

LEO LUZNIK to Cyclophosphamide

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about Cyclophosphamide.
LEO LUZNIK
Connection Strength
14.782
Cyclophosphamide
  1. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022 01 27; 139(4):608-623.
    View in: PubMed
    Score: 0.665
  2. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
    View in: PubMed
    Score: 0.658
  3. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):513-521.
    View in: PubMed
    Score: 0.573
  4. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019 11 21; 134(21):1802-1810.
    View in: PubMed
    Score: 0.571
  5. Post-transplantation cyclophosphamide for chimerism-based tolerance. Bone Marrow Transplant. 2019 08; 54(Suppl 2):769-774.
    View in: PubMed
    Score: 0.559
  6. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2019 06; 25(6):1128-1135.
    View in: PubMed
    Score: 0.537
  7. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2018 02; 24(2):343-352.
    View in: PubMed
    Score: 0.494
  8. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica. 2017 05; 102(5):932-940.
    View in: PubMed
    Score: 0.470
  9. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 02; 102(2):391-400.
    View in: PubMed
    Score: 0.461
  10. Might haplo "be the (better) match"? Blood. 2016 Feb 18; 127(7):799-800.
    View in: PubMed
    Score: 0.440
  11. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016 Apr; 53(2):90-7.
    View in: PubMed
    Score: 0.438
  12. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2016; 57(3):666-75.
    View in: PubMed
    Score: 0.430
  13. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11; 124(25):3817-27.
    View in: PubMed
    Score: 0.401
  14. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505.
    View in: PubMed
    Score: 0.400
  15. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014 Sep 25; 124(13):2131-41.
    View in: PubMed
    Score: 0.397
  16. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013 Nov 13; 5(211):211ra157.
    View in: PubMed
    Score: 0.376
  17. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012 Dec; 39(6):683-93.
    View in: PubMed
    Score: 0.352
  18. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov; 17(6):493-9.
    View in: PubMed
    Score: 0.305
  19. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul; 47(1-3):65-77.
    View in: PubMed
    Score: 0.298
  20. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22; 115(16):3224-30.
    View in: PubMed
    Score: 0.290
  21. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010 Jan; 59(1):137-48.
    View in: PubMed
    Score: 0.279
  22. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun; 14(6):641-50.
    View in: PubMed
    Score: 0.258
  23. Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight. Blood Rev. 2023 11; 62:101093.
    View in: PubMed
    Score: 0.181
  24. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
    View in: PubMed
    Score: 0.177
  25. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8.
    View in: PubMed
    Score: 0.165
  26. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 01; 98(12):3456-64.
    View in: PubMed
    Score: 0.164
  27. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 06 20; 39(18):1971-1982.
    View in: PubMed
    Score: 0.158
  28. PTCy and "The Story of the Three Bears". Bone Marrow Transplant. 2021 04; 56(4):765-766.
    View in: PubMed
    Score: 0.153
  29. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV. 2020 09; 7(9):e602-e610.
    View in: PubMed
    Score: 0.149
  30. Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020; 11:636.
    View in: PubMed
    Score: 0.147
  31. PTCY keeps on giving! Blood. 2019 09 12; 134(11):848-849.
    View in: PubMed
    Score: 0.141
  32. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019 09 10; 3(17):2608-2616.
    View in: PubMed
    Score: 0.141
  33. Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Invest. 2019 05 06; 129(6):2189-2191.
    View in: PubMed
    Score: 0.138
  34. Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. Biol Blood Marrow Transplant. 2018 06; 24(6):1108-1110.
    View in: PubMed
    Score: 0.128
  35. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant. 2018 05; 24(5):1099-1102.
    View in: PubMed
    Score: 0.126
  36. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018 01 11; 131(2):247-262.
    View in: PubMed
    Score: 0.123
  37. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1903-1909.
    View in: PubMed
    Score: 0.121
  38. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017 03 09; 129(10):1389-1393.
    View in: PubMed
    Score: 0.117
  39. Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2017 Apr; 23(4):612-617.
    View in: PubMed
    Score: 0.117
  40. Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen. Transplantation. 2016 Dec; 100(12):e140-e146.
    View in: PubMed
    Score: 0.116
  41. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
    View in: PubMed
    Score: 0.116
  42. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia. 2016 10; 30(10):2102-2106.
    View in: PubMed
    Score: 0.112
  43. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
    View in: PubMed
    Score: 0.109
  44. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Jan; 22(1):112-8.
    View in: PubMed
    Score: 0.107
  45. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016 Jan; 13(1):10-24.
    View in: PubMed
    Score: 0.106
  46. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
    View in: PubMed
    Score: 0.106
  47. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
    View in: PubMed
    Score: 0.105
  48. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
    View in: PubMed
    Score: 0.103
  49. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016 Jan; 96(1):27-35.
    View in: PubMed
    Score: 0.103
  50. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014 Mar; 20(3):314-8.
    View in: PubMed
    Score: 0.094
  51. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1514-7.
    View in: PubMed
    Score: 0.092
  52. Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant. 2013 Oct; 48(10):1335-41.
    View in: PubMed
    Score: 0.091
  53. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91.
    View in: PubMed
    Score: 0.087
  54. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2011 Jul; 46(7):1012-3.
    View in: PubMed
    Score: 0.076
  55. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
    View in: PubMed
    Score: 0.072
  56. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18; 115(11):2136-41.
    View in: PubMed
    Score: 0.072
  57. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct; 42(8):523-7.
    View in: PubMed
    Score: 0.065
  58. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023 06 22; 141(25):3031-3038.
    View in: PubMed
    Score: 0.046
  59. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age =55 Years. Transplant Cell Ther. 2023 03; 29(3):182.e1-182.e8.
    View in: PubMed
    Score: 0.044
  60. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 03; 29(3):208.e1-208.e6.
    View in: PubMed
    Score: 0.044
  61. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplant Cell Ther. 2023 04; 29(4):267.e1-267.e5.
    View in: PubMed
    Score: 0.044
  62. Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide. Blood Adv. 2022 09 13; 6(17):4994-5008.
    View in: PubMed
    Score: 0.043
  63. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma. 2022 12; 63(12):2987-2991.
    View in: PubMed
    Score: 0.043
  64. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplant Cell Ther. 2022 05; 28(5):259.e1-259.e11.
    View in: PubMed
    Score: 0.042
  65. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8(7):377-86.
    View in: PubMed
    Score: 0.041
  66. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):260-269.
    View in: PubMed
    Score: 0.041
  67. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 11; 27(11):909.e1-909.e6.
    View in: PubMed
    Score: 0.040
  68. Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. Transplant Cell Ther. 2021 10; 27(10):863.e1-863.e5.
    View in: PubMed
    Score: 0.040
  69. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020 10 27; 4(20):5078-5088.
    View in: PubMed
    Score: 0.038
  70. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 12; 26(12):2306-2310.
    View in: PubMed
    Score: 0.038
  71. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020 08 25; 4(16):3913-3925.
    View in: PubMed
    Score: 0.038
  72. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant. 2020 11; 26(11):2075-2081.
    View in: PubMed
    Score: 0.038
  73. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biol Blood Marrow Transplant. 2020 09; 26(9):1679-1688.
    View in: PubMed
    Score: 0.037
  74. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020 04 28; 4(8):1770-1779.
    View in: PubMed
    Score: 0.037
  75. Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. Biol Blood Marrow Transplant. 2020 03; 26(3):502-508.
    View in: PubMed
    Score: 0.036
  76. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 09 10; 3(17):2581-2585.
    View in: PubMed
    Score: 0.035
  77. Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020 01; 55(1):40-47.
    View in: PubMed
    Score: 0.034
  78. Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. J Immunother. 2019 04; 42(3):73-80.
    View in: PubMed
    Score: 0.034
  79. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):1022-1028.
    View in: PubMed
    Score: 0.031
  80. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016 Apr 12; 9:35.
    View in: PubMed
    Score: 0.028
  81. Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. Leuk Lymphoma. 2013 Mar; 54(3):655-7.
    View in: PubMed
    Score: 0.022
  82. High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma. 2011 Nov; 52(11):2076-81.
    View in: PubMed
    Score: 0.020
  83. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May; 14(5):499-509.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.